Mark Bittinger

7.4k total citations · 2 hit papers
20 papers, 4.6k citations indexed

About

Mark Bittinger is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mark Bittinger has authored 20 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Mark Bittinger's work include Cancer Immunotherapy and Biomarkers (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and CAR-T cell therapy research (3 papers). Mark Bittinger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and CAR-T cell therapy research (3 papers). Mark Bittinger collaborates with scholars based in United States, France and Canada. Mark Bittinger's co-authors include Valeria R. Fantin, Edward M. Driggers, Stefan Größ, Shengfang Jin, Hyun Gyung Jang, Shinsan M. Su, Lenny Dang, Katharine Yen, Marie C. Keenan and Joshua D. Rabinowitz and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Mark Bittinger

17 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Lenny Dang, David W. White et al. Nature profile →
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

2010 558 citations Stefan Größ, Rob A. Cairns et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Bittinger United States	14	2.8k	2.1k	1.5k	594	587	20	4.6k
Stefan Größ United States	17	3.5k 1.3×	2.8k 1.3×	1.8k 1.2×	691 1.2×	570 1.0×	27	5.5k
Shengfang Jin United States	16	3.9k 1.4×	2.5k 1.2×	1.7k 1.1×	785 1.3×	766 1.3×	21	5.8k
Kevin M. Marks United States	9	2.6k 0.9×	1.8k 0.9×	1.3k 0.9×	417 0.7×	454 0.8×	14	4.2k
Marie C. Keenan United States	6	2.6k 0.9×	2.0k 0.9×	1.3k 0.9×	414 0.7×	401 0.7×	8	4.1k
Katharine Yen United States	22	3.6k 1.3×	2.8k 1.3×	2.1k 1.4×	1.2k 2.1×	662 1.1×	38	5.9k
Shinsan M. Su United States	13	4.4k 1.6×	3.5k 1.7×	2.4k 1.6×	1.4k 2.3×	658 1.1×	16	6.9k
Lenny Dang United States	26	5.0k 1.8×	3.7k 1.8×	2.3k 1.5×	1.4k 2.3×	1.5k 2.5×	50	8.3k
Michael G. Kharas United States	36	4.2k 1.5×	1.6k 0.7×	869 0.6×	1.1k 1.9×	713 1.2×	77	5.6k
W.K. Alfred Yung United States	40	2.9k 1.1×	1.3k 0.6×	3.1k 2.0×	255 0.4×	1.4k 2.3×	108	5.9k
Russell O. Pieper United States	44	3.9k 1.4×	1.7k 0.8×	1.9k 1.3×	179 0.3×	2.1k 3.5×	105	6.7k

Countries citing papers authored by Mark Bittinger

Since Specialization

Citations

This map shows the geographic impact of Mark Bittinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bittinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bittinger more than expected).

Fields of papers citing papers by Mark Bittinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bittinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bittinger. The network helps show where Mark Bittinger may publish in the future.

Co-authorship network of co-authors of Mark Bittinger

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bittinger. A scholar is included among the top collaborators of Mark Bittinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bittinger. Mark Bittinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilson, Henry S., Kimberly Straley, Maulasri Bhatta, et al.. (2024). Abstract 903: AURIGIN: A comprehensive single-cell OMICs atlas of human development and an AI/ML framework to classify and identify the drivers of tumor plasticity and altered cellular state. Cancer Research. 84(6_Supplement). 903–903.

Straley, Kimberly, Iléana Antony‐Debré, Maulasri Bhatta, et al.. (2024). Abstract 5795: Potent and selective degradation of KAT2A and KAT2B induces profound cell state changes and inhibits growth of AML, SCLC and NEPC model systems. Cancer Research. 84(6_Supplement). 5795–5795.

Methot, Joey L., Xavier Fradera, Charles A. Lesburg, et al.. (2021). Identification of Potent Reverse Indazole Inhibitors for HPK1. ACS Medicinal Chemistry Letters. 12(3). 459–466. 24 indexed citations

Vara, Brandon, Samuel M. Levi, David A. Candito, et al.. (2021). Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds. ACS Medicinal Chemistry Letters. 12(4). 653–661. 31 indexed citations

Wang, Yun, Kelvin Zhang, Peter Georgiev, et al.. (2020). Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLoS ONE. 15(12). e0243145–e0243145. 29 indexed citations

Lizotte, Patrick H., Ruey‐Long Hong, Troy A. Luster, et al.. (2018). A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research. 6(12). 1511–1523. 69 indexed citations

Lizotte, Patrick H., Troy A. Luster, Megan E. Cavanaugh, et al.. (2018). Abstract 4935: High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing. Cancer Research. 78(13_Supplement). 4935–4935. 4 indexed citations

Hanna, Glenn J., Hongye Liu, Robert E. Jones, et al.. (2017). Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology. 67. 61–69. 40 indexed citations

Lizotte, Patrick H., Robert E. Jones, Lauren Keogh, et al.. (2016). Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Scientific Reports. 6(1). 31745–31745. 20 indexed citations

10.

Lizotte, Patrick H., Elena V. Ivanova, Mark Bittinger, & Kwok‐Kin Wong. (2016). Abstract A132: Multi-parametric profiling of non-small cell lung cancers reveals distinct immunophenotypes. Cancer Immunology Research. 4(11_Supplement). A132–A132. 2 indexed citations

11.

Bittinger, Mark, Zhaohui Xiong, Somnath Bandyopadhyay, et al.. (2015). TMEM203 Is a Novel Regulator of Intracellular Calcium Homeostasis and Is Required for Spermatogenesis. PLoS ONE. 10(5). e0127480–e0127480. 24 indexed citations

12.

Middleton, Richard E., Gang Lü, Wenhua Gao, et al.. (2015). Abstract 5436: Targeting oncoproteins via disruption of proteostasis: Identification of oncoprotein destabilizing agents using luciferase tagged oncoproteins. Cancer Research. 75(15_Supplement). 5436–5436.

13.

Größ, Stefan, Rob A. Cairns, Mark D. Minden, et al.. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of Experimental Medicine. 207(2). 339–344. 558 indexed citations breakdown →

14.

Fantin, Valeria R., Lenny Dang, David W. White, et al.. (2010). Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Cancer Research. 70(8_Supplement). 33–33. 4 indexed citations

15.

Dang, Lenny, David W. White, Stefan Größ, et al.. (2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 465(7300). 966–966. 399 indexed citations

16.

Dang, Lenny, David W. White, Stefan Größ, et al.. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462(7274). 739–744. 3067 indexed citations breakdown →

17.

Bittinger, Mark, Elizabeth McWhinnie, Jodi Meltzer, et al.. (2004). Activation of cAMP Response Element-Mediated Gene Expression by Regulated Nuclear Transport of TORC Proteins. Current Biology. 14(23). 2156–2161. 194 indexed citations

18.

Bittinger, Mark, Linh P. Nguyen, & Christopher A. Bradfield. (2003). Aspartate Aminotransferase Generates Proagonists of the Aryl Hydrocarbon Receptor. Molecular Pharmacology. 64(3). 550–556. 90 indexed citations

19.

Bittinger, Mark & Jo Handelsman. (2000). Identification of Genes in the RosR Regulon of Rhizobium etli. Journal of Bacteriology. 182(6). 1706–1713. 32 indexed citations

20.

Bittinger, Mark, Jocelyn L. Milner, Barry Saville, & Jo Handelsman. (1997). rosR, a Determinant of Nodulation Competitiveness in Rhizobium etli. Molecular Plant-Microbe Interactions. 10(2). 180–186. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact